A premium-priced private placement gives Agenus $85 million upfront as it shifts resources to one colon-cancer trial.
Agenus shifts to BOT+BAL in neoadjuvant MSS colon cancer; $85M raise extends runway to 2031. Click here to read this latest ...
Key Points Interested in Agenus Inc.? Here are five stocks we like better. Agenus is prioritizing its Phase 3 ROBBIN trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results